Exact Sciences Presents Data Demonstrating Advancement in …
WEB3 days ago · Exact Sciences News(108) Partnerships(14) Recommended Content. July 17, 2024. Exact Sciences Awards Grants to 28 Organizations Focused on Increasing Colorectal Cancer Screening. May 24, 2024. Exact Sciences Demonstrates Continued Leadership in Early Cancer Diagnosis and Improved Health Outcomes for Patients with Multiple Data Presentations at ...
Exact Sciences’ colon cancer blood test shows initial promise - STAT
WEB3 days ago · By Jonathan Wosen. Sept. 16, 2024. West Coast Biotech & Life Sciences Reporter. Exact Sciences, which has for years sold a stool-based colon cancer test, on Monday announced that a blood-based ...
Exact Sciences Presents Data Demonstrating Advancement in …
WEB3 days ago · MADISON, Wis., September 16, 2024--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced performance data for its blood-based colorectal ...
Buy Rating Affirmed for Exact Sciences on Robust CRC Test …
WEB3 days ago · Exact Sciences (EXAS) Company Description: Founded in 1995, Wisconsin-based Exact Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of ...
Exact Sciences says data support its colon cancer blood test
WEB3 days ago · Exact Sciences released data from a study of its blood-based colorectal cancer screening test that showed sensitivities of 88.3% for colorectal cancer and 31.2% for advanced precancerous lesions. Specificity, a measure of how well a test identifies people who do not have cancer, was 90.1% for negative samples confirmed by colonoscopy.
Press Releases - Exact Sciences
WEB3 days ago · Exact Sciences Announces First Patient Enrolled in its Multi-Cancer Early Detection (MCED) Falcon Registry Real-World Evidence Study.
Exact Sciences Debuts Positive Topline Results for Trial of Blood …
WEB2 days ago · Performance data for a blood-based colorectal cancer (CRC) screening test under development by Exact Sciences demonstrated an 88.3% sensitivity for CRC and a 31.2% sensitivity for advanced precancerous lesions, the latter at a specificity of 90.1% for negative samples confirmed by colonoscopy, according to a statement from the company. 1
Exact Sciences Announces Fourth Quarter 2023 Results
WEBMADISON, Wis., Feb. 21, 2024 — Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $647 million for the fourth quarter of 2023 and $2.50 billion for the full year of 2023, both ended Dec. 31, 2023.
2024-09-16 | Exact Sciences Presents Data Demonstrating
WEB3 days ago · Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced performance data for its blood-based colorectal cancer (CRC) screening test. Results show sensitivities of 88.3% for CRC and 31.2% for advanced precancerous lesions at specificity of 90.
Exact Sciences Presents Data Demonstrating Advancement in …
WEB3 days ago · About Exact Sciences Corp. ... This news release contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs or strategies regarding the future. These ...
- Some results have been removed